⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
globenewswire.com
MBRX
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
globenewswire.com
MBRX
Moleculin Launches CEO Corner Platform to Share Strategic Insights
globenewswire.com
MBRX
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026
accessnewswire.com
AKTX
DCOY
GRI
MBRX
AIM
BULL
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
globenewswire.com
MBRX
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
globenewswire.com
MBRX
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
globenewswire.com
MBRX
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
globenewswire.com
MBRX
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
globenewswire.com
MBRX
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
globenewswire.com
MBRX